Vera Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2025-07-07: Study NCT06983028; Company role Lead sponsor; Phase Phase 2; Status Recruiting.
- 2025-05-29: Study NCT07020923; Company role Lead sponsor; Phase Phase 2; Status Active not recruiting.
- 2024-12-01: Study NCT06674577; Company role Lead sponsor; Phase Phase 2; Status Enrolling by invitation.
- 2023-06-29: Study NCT04716231; Company role Lead sponsor; Phase Phase 3; Status Active not recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2025-07-07 | NCT06983028 Atacicept in Multiple Glomerular Diseases | Lead sponsor | Phase 2 | Recruiting | pMN; IgAN; Nephrotic Syndrome; MCD; FSGS | 250 | 2027-11 |
| 2025-05-29 | NCT07020923 Monthly Dosing of Atacicept in IgAN | Lead sponsor | Phase 2 | Active not recruiting | IgA Nephropathy (IgAN); Berger Disease | 90 | 2027-09 |
| 2024-12-01 | NCT06674577 A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept | Lead sponsor | Phase 2 | Enrolling by invitation | IgA Nephropathy (IgAN); Renal and Urinary Disorders; Berger Disease | 750 | 2031-05-21 |
| 2023-06-29 | NCT04716231 Atacicept in Subjects With IgA Nephropathy | Lead sponsor | Phase 3 | Active not recruiting | IgA Nephropathy; Berger Disease | 376 | 2028-07 |
| 2022-11-02 | NCT05609812 Atacicept in Subjects With Active Lupus Nephritis (COMPASS) | Lead sponsor | Phase 3 | Withdrawn | Lupus Nephritis (LN) | 0 | 2028-12-15 |
| 2020-08-05 | NCT04294472 A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients | Lead sponsor | Phase 2 | Completed Results posted | BK Virus Infection | 30 | 2022-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |